Krystal Biotech: cross-border access for the specialty portfolio

Quick orientation

Krystal Biotech, Inc. is a US-based commercial-stage gene therapy company headquartered in Pittsburgh, Pennsylvania. The company developed the first FDA-approved redosable, topical gene therapy and is the leader in cutaneous and inhaled HSV-1 vector platforms. Krystal's pipeline targets rare epithelial diseases - skin, lung, and ophthalmic indications - where systemic gene therapy is impractical and topical delivery is the breakthrough. Krystal trades on NASDAQ as KRYS and is a focused commercial operator with a development pipeline that extends the platform into respiratory and ocular rare disease. FDA approval scale is currently one marketed product, with multiple Phase 1/2 candidates in active development. The company's commercial commitment to a redosable topical gene therapy modality represents a new chapter in rare-disease gene therapy: unlike single-administration adeno-associated virus (AAV) gene therapies, Vyjuvek is applied weekly and is tolerated for redosing over years.

Krystal Biotech portfolio in cross-border NPP scope

Vyjuvek (beremagene geperpavec-svdt) is a topical gel gene therapy approved by the FDA in May 2023 for the treatment of wounds in patients six months of age and older with dystrophic epidermolysis bullosa (DEB), including both recessive (RDEB) and dominant (DDEB) subtypes. Vyjuvek delivers functional copies of the COL7A1 gene directly to wound sites and is the first and only FDA-approved redosable gene therapy. List pricing is in the range of US$631,000 per year for an average pediatric patient, with weight-dependent variation. Vyjuvek requires cold-chain handling at -65 to -90 degrees C frozen and is reconstituted at the point of care; the prepared gel is applied weekly by a healthcare professional to open or recently-closed wounds. The GEM-1 and GEM-3 Phase 3 trials demonstrated wound closure at six months in 67 percent of treated wounds versus 22 percent for placebo, with durability extending in long-term follow-up. The product is supplied as a single-dose vial of frozen suspension co-packaged with excipient gel.

Krystal's pipeline extends to KB407 (inhaled HSV-1 vector for cystic fibrosis), KB408 (inhaled gene therapy for alpha-1 antitrypsin deficiency), KB707 (intratumoral oncology candidate), KB801 (ophthalmic candidate for neurotrophic keratitis), and KB104 (topical candidate for Netherton syndrome). These are investigational and not currently FDA-approved; Reserve Meds does not source investigational product through NPP channels. Only FDA-approved commercial inventory is in scope for our coordination.

Why patients route through cross-border NPP

Dystrophic epidermolysis bullosa is an ultra-rare condition - global prevalence estimates run between two and ten cases per million population, meaning the addressable population in any given country is typically in the dozens to low hundreds. Outside the United States, Vyjuvek is not yet approved or reimbursed in most jurisdictions, including the GCC, India, and most of South and Southeast Asia. The European Commission approved beremagene geperpavec under the trade name Vyjuvek in February 2025, but country-by-country reimbursement and named-patient channels remain uneven through 2026. Families with a confirmed COL7A1 diagnosis frequently encounter a registration gap: the diagnosis is unambiguous, the genetic mutation is known, but local pharmacies cannot order the product because it is not on the national formulary. Cross-border named patient access is, in many countries, the only pathway available before local launch.

The clinical case for Vyjuvek is unusually clear. The Phase 3 efficacy data is robust, the safety profile is favorable, and the treatment burden (weekly topical application) is acceptable to families. Pediatric patients are the typical Reserve Meds inbound profile, often referred by a dermatology or pediatric genetics center that has confirmed the COL7A1 mutation but cannot prescribe the product locally. Patient families who reach Reserve Meds typically have already exhausted standard wound-care approaches, donor skin grafting where applicable, and other supportive measures.

Common cross-border destinations

The highest-frequency NPP destinations for Vyjuvek from US-approved inventory are the United Arab Emirates, Saudi Arabia, India, Qatar, and Kuwait. Demand correlates with concentrations of pediatric genetics and rare-disease referral centers in Dubai, Abu Dhabi, Riyadh, Jeddah, Hyderabad, Mumbai, Bangalore, Delhi, and Doha. Family-level co-payment and self-pay capacity in these jurisdictions makes private cross-border pathways viable where public reimbursement is years away.

Manufacturer engagement posture

Reserve Meds coordinates Krystal-sourced US commercial product through DSCSA-compliant US specialty distributors. We are not affiliated with, owned by, or contracted as a distributor of Krystal Biotech. Our role is patient-facing coordination on behalf of named individual patients with a verified prescription from a treating physician, sourcing approved commercial inventory through licensed US wholesale channels with full chain-of-custody documentation. For Krystal medical affairs or commercial teams interested in patient access pathways outside the United States, our BD contact is [email protected].

What Reserve Meds provides

For each Krystal Biotech product request, Reserve Meds coordinates: prescription verification with the treating physician; DSCSA serialized chain-of-custody documentation from the FDA-registered manufacturer through licensed US wholesalers to the named patient; validated frozen cold-chain shipping with temperature data-loggers and remediation protocols; destination-country regulatory documentation including Ministry of Health named-patient approvals, import permits, and customs clearance documentation; and a dedicated coordinator who manages each shipment from prescription to delivery. Coordinator email and direct phone are issued at request acceptance.

Clinical governance and prescription review

Every prescription for a product on this page is reviewed by a US-licensed pharmacist before dispensing. Reserve Meds does not substitute generic equivalents for branded specialty products without an explicit prescriber instruction, and we do not dispense any product whose chain-of-custody we cannot serialize back to the FDA-authorised manufacturer or its licensed wholesale partner. Our clinical review confirms indication-on-label appropriateness based on the documentation submitted by the treating physician, identifies any standard drug-drug interaction or contraindication concerns, and confirms that the requested dose, dosing schedule, and dosage form match the prescription. Where the prescription is unclear or where the indication on the prescription is off-label, our pharmacist contacts the prescriber directly. We do not provide medical advice to patients beyond drug-information counseling at dispensing.

Supply chain integrity

Supply integrity is the foundation of Reserve Meds operations. Every shipment carries a serialized DSCSA pedigree document confirming the chain of ownership from the FDA-registered manufacturer or its authorised distributor through a licensed US wholesale distributor to Reserve Meds and onward to the named patient. We do not source through parallel-import channels, third-country re-import, or unverified online wholesale markets. Cold-chain shipments are packed in qualified shippers with temperature data-loggers reading and logging temperature throughout the journey; data-logger reads are reviewed on arrival, and any out-of-specification excursion triggers our quality-hold protocol. For frozen products such as gene therapies and certain antibody-drug conjugates, we use validated frozen-shipper systems with dry-ice replenishment as required.

Destination-country regulatory pathways

Cross-border named patient access operates under jurisdiction-specific regulatory frameworks. In the United Arab Emirates, the Ministry of Health and Prevention (MOHAP) and Dubai Health Authority operate import-permit pathways for unregistered or restricted medicines on a named-patient basis. Saudi Arabia, Qatar, Kuwait, Bahrain, and Oman each operate analogous Ministry of Health named-patient frameworks with country-specific documentation requirements. India operates a personal-import pathway under the Drugs and Cosmetics Rules for quantities consistent with personal therapeutic use, typically up to three months supply per shipment. Turkey, Egypt, Jordan, Lebanon, and Morocco each operate distinct named-patient or import-permit pathways. Reserve Meds maintains current regulatory intelligence for each of these jurisdictions and prepares the documentation package required for each shipment.

What to expect through the coordination process

Patients beginning a request receive an initial coordinator contact within one business day of submission. The coordinator reviews the prescription, identifies the documentation required for the destination country, and provides an indicative cost range. Once required documents are uploaded - prescription, prescriber license verification, patient identification, and any indication-specific documentation such as genetic test results or biomarker reports - we issue a firm quote inclusive of product cost, packaging, shipping, regulatory documentation, and our coordination fee. Patients confirm acceptance of the firm quote before any sourcing or shipping is initiated, and Reserve Meds does not collect any deposit at intake. Once the firm quote is accepted and payment is received, the coordinator initiates sourcing through our licensed wholesale partners and prepares the destination-country regulatory package. Typical end-to-end timing from accepted quote to delivery is two to four weeks for ambient-shipped products and three to five weeks for cold-chain shipments, with variability driven by destination-country customs and regulatory turnaround times.

Not affiliated with the manufacturer

Reserve Meds is an independent operator of named patient program coordination. We are not a subsidiary, affiliate, authorised distributor, or licensed representative of any pharmaceutical manufacturer, and no statement on this page should be read as a partnership, endorsement, or representation by the named manufacturer. Trade names and product references on this page are used for informational purposes to identify the FDA-approved products that Reserve Meds coordinates through US specialty wholesale channels on behalf of named individual patients.

Privacy and data handling

Patient data submitted to Reserve Meds is handled under our HIPAA-aligned privacy policy and our destination-country data protection commitments. We minimise data collection to what is necessary for prescription verification, regulatory documentation, and shipping logistics. Patient identifiable information is shared with US wholesalers, destination-country regulatory authorities, and shipping carriers only as required to complete the coordination, and is not used for any marketing purpose.

Next step for patients

Patients or caregivers with a confirmed dystrophic epidermolysis bullosa diagnosis and a treating-physician prescription can begin a request now. Start a Vyjuvek request ›

For other Krystal Biotech products, please use our general request form and note the product name. Start a request ›

Next step for Krystal Biotech teams

Krystal Biotech commercial, medical affairs, or access teams interested in cross-border NPP coordination for non-US territories can reach our BD team at [email protected]. We do not require formal partnership to coordinate named-patient export of FDA-approved Krystal commercial product through US specialty wholesale channels; we welcome direct engagement on patient identification, regulatory navigation, and post-shipment pharmacovigilance.

Reserved for you.